PLRX Stock Summary and Trading Ideas (Pliant Therapeutics | NASDAQ:PLRX)

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics trades on the NASDAQ stock market under the symbol PLRX.

As of December 19, 2025, PLRX stock price climbed to $1.23 with 1,075,160 million shares trading.

PLRX has a beta of 1.37, meaning it tends to be more sensitive to market movements. PLRX has a correlation of 0.03 to the broad based SPY ETF.

PLRX has a market cap of $75.58 million. This is considered a Micro Cap stock.

In the last 3 years, PLRX traded as high as $36.64 and as low as $1.10.

The top ETF exchange traded funds that PLRX belongs to (by Net Assets): VTI, VXF, IBB, VHT, IWC.

PLRX has underperformed the market in the last year with a return of -90.8%, while the SPY ETF gained +18.1%. In the last 3 month period, PLRX fell short of the market, returning -14.0%, while SPY returned +2.8%. However, in the most recent 2 weeks PLRX has outperformed the stock market by returning +1.7%, while SPY returned -0.5%.

PLRX support price is $1.15 and resistance is $1.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLRX shares will trade within this expected range on the day.